Fintel on MSN9h
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
TTD Stock Insight: Evercore Slaps with Rating Downgrade and Price Target Trim
Five-star-rated analyst Mark Mahaney at Evercore ISI has downgraded his rating from Buy to Hold on The Trade Desk (TTD) after ...
Evercore ISI Remains a Hold on Tyler Technologies (TYL)
Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of ...
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Evercore ISI Issues Positive Forecast for Confluent (NASDAQ:CFLT) Stock Price
Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...
Evercore ISI Boosts The Carlyle Group (NASDAQ:CG) Price Target to $52.00
The Carlyle Group (NASDAQ:CG – Get Free Report) had its price target hoisted by analysts at Evercore ISI from $51.00 to $52.00 in a report issued on Wednesday,Benzinga reports. The firm presently has ...
Hosted on MSN1d
Evercore ISI Group Downgrades Trade Desk (TTD)
Fintel reports that on February 13, 2025, Evercore ISI Group downgraded their outlook for Trade Desk (NasdaqGM:TTD) from ...
Modern Healthcare1d
VillageMD taps advisers as Walgreens pursues exit plan
Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...
CRISPR Therapeutics stock rises following analyst upgrade
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.